Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29976235 | 1.00 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL30735974 | 0.98 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL354001 | 0.98 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL9929149 | 0.86 | NPC1 (0.63) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL148855 | 0.85 | ALDH1A1 (0.53) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL147211 | 0.85 | SMN1; SMN2 (0.54) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL29923727 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL632502 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL30735953 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL858839 | 0.83 | ALDH1A1 (0.66) | ALDH1A1HPGDCYP3A4MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324761-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024121632-A1 | USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) | CRISPR THERAPEUTICS AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024059237-A2 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-01-01 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6608027-B1 | Macrocyclic small peptides of low molecular weight that are inhibitory to NS3 protease of hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2003-08-19 | — | — | US | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1169339-A1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000059929-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | ALDH1A1 576/4885HPGD 1330/4885CYP3A4 1124/4885 |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | ALDH1A1 1567/4885HPGD 308/4885CYP3A4 3752/4885 |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | VIP, FURIN, RNASE1 | ALDH1A1 1770/4885HPGD 2358/4885CYP3A4 445/4885 |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | TMBIM6, RPS6KB1, RACK1 | ALDH1A1 4543/4885HPGD 4547/4885CYP3A4 4655/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | ALDH1A1 2672/4885HPGD 3503/4885CYP3A4 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.